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Sucrose stabilization of Respiratory Syncytial Virus (RSV) during
nebulization and experimental infection
Abstract
Background Respiratory syncytial virus (RSV) is a common respiratory pathogen that can cause severe
pneumonia. In vivo studies of RSV can be difficult due to variation in viral infection and disease severity in
some animal models. Factors that may contribute to the variation are decreases in viral titer due to preparation
and storage and method of virus administration. Nebulization is one method of RSV administration that
provides even distribution of virus to all lung lobes; however, the exact quantity of the virus killed by
nebulization is not defined. To test the hypothesis that sucrose enhances RSV stability and infectivity, a series
of in vitro experiments were conducted with RSV strain Memphis 37 stored at varying concentrations (0%,
3%, 5%, 8%, 10%, 15%, and 20%) of sucrose as a possible cryo- and nebulization protectant. The optimal in
vitro concentration was then assessed in vivo in a lamb model.
Methods Prior to titering the virus on HEp-2 cells, the various virus solutions were subjected to one freeze-
thaw cycle and one nebulization cycle. Forty-eight hours after viral plating, infectious foci were detected and
counted using immunofluorescent imaging. Titers were determined after freeze-thaw and after freeze-thaw
followed by nebulization, then compared to the stock titers (before freezing) as well as to one another to
determine the loss of infectivity. To further test this in vivo, lambs 2 to 3-days-old were infected via
nebulization with RSV using inoculate containing either 20% sucrose or no sucrose followed by assessments
of infection severity.
Results Nebulization of virus in 0% sucrose resulted in a 0.580 log reduction in infectivity while virus in 20%
sucrose exhibited a 0.297 log reduction. In vivo studies demonstrated that 20% sucrose enhanced RSV lesions
and antigen distribution.
Conclusions The data suggests that both nebulization and freeze-thawing of RSV in the absence of sucrose
cause unacceptable losses in viral infectivity and that sucrose acts as a RSV protectant in both regards.
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Sucrose stabilization of Respiratory Syncytial Virus
(RSV) during nebulization and experimental
infection
Drew D Grosz, Albert van Geelen, Jack M Gallup, Shannon J Hostetter, Rachel J Derscheid and Mark R Ackermann*
Abstract
Background: Respiratory syncytial virus (RSV) is a common respiratory pathogen that can cause severe pneumonia.
In vivo studies of RSV can be difficult due to variation in viral infection and disease severity in some animal models.
Factors that may contribute to the variation are decreases in viral titer due to preparation and storage and method
of virus administration. Nebulization is one method of RSV administration that provides even distribution of virus to
all lung lobes; however, the exact quantity of the virus killed by nebulization is not defined. To test the hypothesis
that sucrose enhances RSV stability and infectivity, a series of in vitro experiments were conducted with RSV strain
Memphis 37 stored at varying concentrations (0%, 3%, 5%, 8%, 10%, 15%, and 20%) of sucrose as a possible
cryo- and nebulization protectant. The optimal in vitro concentration was then assessed in vivo in a lamb model.
Methods: Prior to titering the virus on HEp-2 cells, the various virus solutions were subjected to one freeze-thaw
cycle and one nebulization cycle. Forty-eight hours after viral plating, infectious foci were detected and counted
using immunofluorescent imaging. Titers were determined after freeze-thaw and after freeze-thaw followed by
nebulization, then compared to the stock titers (before freezing) as well as to one another to determine the loss of
infectivity. To further test this in vivo, lambs 2 to 3-days-old were infected via nebulization with RSV using inoculate
containing either 20% sucrose or no sucrose followed by assessments of infection severity.
Results: Nebulization of virus in 0% sucrose resulted in a 0.580 log reduction in infectivity while virus in 20%
sucrose exhibited a 0.297 log reduction. In vivo studies demonstrated that 20% sucrose enhanced RSV lesions and
antigen distribution.
Conclusions: The data suggests that both nebulization and freeze-thawing of RSV in the absence of sucrose cause
unacceptable losses in viral infectivity and that sucrose acts as a RSV protectant in both regards.
Keywords: Respiratory Syncytial Virus, RSV, Nebulization, Sucrose
Background
Globally, respiratory syncytial virus (RSV) is estimated
to cause 64 million cases of respiratory disease annually
with the majority of cases occurring in children under
the age of 5 and approximately 160,000 cases resulting
in death [1-7]. In the United States, RSV is associated
with an estimated 20-25% of pneumonia cases in children
and 70% of bronchiolitis cases requiring hospitalization
[1,2]. While much has been learned about the virus and
disease pathogenesis, there are no fully effective vaccines
or therapeutic regimens [8,9]. Animal models and in vitro
studies have been instrumental in advancing knowledge of
RSV pathogenesis; however, comparison of methodologies
of studies is lacking.
Nebulization has been used as a method of RSV in-
oculation in various experimental animal models [10,11].
Other routes of inoculation include intranasal, intraocu-
lar, and intratracheal administration, while fiber optic
bronchoscopic deposition has also been used success-
fully as a means of viral inoculation to specific regions
of the lung (11). While each method has its advantages
and disadvantages, nebulization results in a uniform dis-
tribution of virus throughout all lung lobes; however the
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extent to which nebulization damages or disrupts RSV
has not yet been explored.
Sucrose has been used to protect RSV and other viral
samples during shipping, storage and with swabs of virus
[12-14]. The goals of this study were to: 1) determine
the effects of freeze-thawing and nebulization on RSV
stability/infectivity using RSV inoculum containing dif-
ferent concentrations of sucrose in vitro cultured in
HEp-2 cells and, 2) test the extent to which the addition
of sucrose to nebulized RSV inoculum affects RSV dis-
ease severity in vivo in perinatal lambs infected with a
human strain of RSV. Lambs provide a good model of
neonatal RSV infection. Ovine lung has similar develop-
ment, structure, and cellularity to those of human in-
fants [11]. Also, lambs are susceptible to human strains
of RSV and develop lesions similar to those in human
infants [11,15-17].
Methods
Experimental design of in vitro studies
Growing HEp-2 cells
HEp-2 cells were grown on 75 cm2 and/or 300 cm2 tis-
sue culture flasks with a vent screw cap (TPP®) using
12 mL or 45 mL media, respectively, of Dulbecco’s
Modification of Eagle’s Medium (DMEM) (Mediatech,
Inc. Cat. No. 10-013-CV), 10% fetal bovine serum (FBS)
(Atlanta Biologicals Cat. No. S11550), 50 μg/mL of kana-
mycin sulfate (Invitrogen Cat. No. 11815–032), and in-
cubated at 37°C at 5% CO2 and 93% humidity. Cells
were passaged 1:6 every 2–3 days, depending on cell
confluence. Twelve-well cell culture plates (Costar®)
were seeded with HEp-2 cells at a concentration of
2-3×105 per well containing 6.5 mL of media. Cell con-
centration was determined prior to passaging by hemo-
cytometer (Bright-Line®) to determine approximate cells
per mL. Cells were allowed to grow overnight prior to
infectious focus assay.
RSV M37 stock and sucrose
RSV Memphis strain 37 (RSV M37) was frozen at vary-
ing sucrose concentrations (0%, 3%, 5%, 8%, 10%, 15%,
and 20%) to assess infectivity after cryo-storage and neb-
ulization. HEp-2 cells were grown, as stated above, and
infected with RSV M37. After 48 hrs, the virus was iso-
lated from the cells after a freeze-thaw cycle (at −80°C)
followed by centrifugation (2500 rpm for 10 min). 5 mL
of the supernatant was then added to varying amounts
of PBS (Sigma Cat. No. P3813-10PAK; 0.138 M NaCl,
0.0027 M KCl, pH 7.4 @ 25°C), 0% sucrose and 10% FBS
solution or PBS, 60% sucrose and 10% FBS solution to
attain desired sucrose concentrations of 0%, 3%, 5%, 8%,
10%, 15%, and 20%. The solution of 60% (w/v) sucrose
in PBS was made, supplemented with 10% FBS and fil-
tered using a Nalgene filter flask and used to accomplish
the various desired final tested concentrations of sucrose
mentioned above. A 0.5 mL aliquot was taken from each
sucrose concentration and stored in a separate tube; this
was used to determine the stock and post freeze-thaw ti-
ters of the virus. After preparation, samples were frozen
at −80°C for about 3 weeks before use. Upon use, sam-
ples were thawed in a 37°C water bath just until ice
disappeared.
Infecting HEp-2 cells with RSV M37 for infectious focus assay
Viral titers were assessed prior to freezing, after freezing,
and following nebulization in a standard infectious focus
assay. Collected condensates of nebulized vapors contain-
ing RSV M37 were used to infect HEp-2 cells. Vapors
were collected using a nebulization apparatus coupled to a
modified cold trap. The nebulization apparatus included: a
nebulizer compressor unit, PARI nebulizer tubing, PARI
Sprint™ nebulizer (PARI LC™), T-port connector, rubber
stopper #3 (22 mm inside diameter), modified garden hose
rubber washer (30 mm outer diameter and 22 mm inside
diameter), and a 250 mL flask (PYREX®). 6 mL of RSV
M37 inoculum containing the varying sucrose concentra-
tions stated above, were individually loaded into the PARI
SprintTM nebulizer and nebulized in three 2-mL amounts
over a 23- minute period. A new nebulizer was used for
each sucrose concentration. The condensed nebulized
vapors within the 250 mL flasks were then diluted in du-
plicate with media in serial dilution fashion from 10−1 to
10−5. HEp-2 cells at a confluency of 75-85% (minimum of
50%) were used for the infectious focus assay. Prior to
viral inoculation, the media within pre-seeded 12-well
plates was discarded. 200 μL of diluted condensed viral
vapor was then transferred to designated HEp-2 cell wells
and allowed to incubate for 1 hr at 37°C to allow virus-to-
cell contact. After 1 hr, 1 mL of media was added to each
well and the plates were again incubated at 37°C for
48 hrs to allow for viral replication. Prior to freezing and
post freezing, stock samples were also titered without the
nebulization process; samples which came from aliquots
of the original virus/sucrose preparations. Titers of these
original pre-frozen viral stocks (with and without sucrose)
ranged from 1.63 × 106 to 2.91 × 106 FFU/mL. Multiplicity
of infection (MOI) for each study was generally between
0.5 and 1. All nebulization and plating was performed in a
class II biosafety cabinet (NUAIRE®).
Determining RSV M37 infected cells
Immunofluorescence microscopy was used to determine
cell infectivity. After the 48-hr incubation period, media
within the wells was discarded and wells were rinsed
once with TBStw [TBS-0.05% Tween 20, pH 7.4 (TBStw)].
Cells were then fixed with 0.5 mL 60% acetone/40%
methanol solution for 1 min. The fixative was then re-
moved and plates were allowed to dry for 2 min. Cells
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were rehydrated with 0.5 mL per well with TBStw and
placed on a rotator (Boekel Scientific, model 260300 F) for
1 min after which well contents were discarded. A 1 mL
blocking solution containing 3% bovine serum albumin
(BSA) (Fisher Scientific, Hanover, IL) in TBStw was added
to each well and plates were placed on the rotator for a
minimum of 30 min, after which well contents were dis-
carded. 325 μL of primary antibody [Meridian, MAb to
RSV Fusion Protein, Cat. No. C87610M, Clone: RSV 3216
(B016)] containing 3% BSA-TBStw at 1:800 dilution was
added to each well and plates were incubated overnight at
4°C on a rocker apparatus, after which well contents were
discarded and wells were rinsed with TBStw. 325 μL of
the secondary antibody (Invitrogen, Goat anti-Mouse Fab’
conjugated to AlexaFluor 488, Cat. No. A11017) contain-
ing 3% BSA-TBStw at 1:800 dilution was then added to
each well and plates were placed on the rotator for a mini-
mum of 30 min, after which well contents were discarded.
Wells were then rinsed twice with 1 mL TBStw. 1 mL
TBStw was then added to each well and fluorescing foci
were visualized using an Olympus CKX41 inverted
microscope with an external florescence bulb; X-Cite
series 120 Q (Lumen Dynamics®). Cell aggregates ≥5 cells
were counted as one infectious focus. Infectious foci per
well were then converted to focus forming units (FFU)
per mL using the following formula: [(arithmetic mean ×
dilution × 1000 μL/mL) / 200 μL assessed = FFU/mL].
Images were taken using an Olympus DP20 camera-
microscope attachment.
Experimental design of in vivo studies
Three groups of 2 to 3-day-old lambs (either sex; Poly-
pay, Suffolk, Dorsett cross breed) were used for the
study. RSV strain (Memphis 37) was grown in HEp-2
cells and delivered (1.25 × 106 FFU/mL) to lambs in
6 mL culture medium using a PARI Sprint™ nebulizer
(fitted with a cone-shaped face mask fitted with a rubber
diaphragm that provided a seal around the mandible and
nose) in three 2-mL increments over a 23 minute period.
One group (n = 6 lambs) received this amount of RSV in
culture media containing 20% sucrose whereas another
group (n = 6 lambs) received this same amount of RSV
in media lacking sucrose; control lambs (n = 2) received
6 mL culture medium (lacking virus) with 20% sucrose,
also by nebulization. After inoculation with RSV, lambs
in all groups received a daily antibiotic (Ceftiofur, 1–
2 mg/kg body weight, intramuscular) to prevent second-
ary bacterial infections. Lamb temperatures, body
weights, respiratory and heart rates were measured daily.
Clinical severity of RSV disease for each lamb was
assessed and scored as previously described [11,17,18].
Lambs were euthanized by sodium pentobarbital overdose
on day 6 post-inoculation (p.i.) when RSV-induced lesions
are maximal in this model [11,17,18]. Throughout the
experiment, lambs received a custom diet (Milk Products
Inc., Chilton, WI, USA) that lacked supplemental iodide,
and the lack of iodide was verified using anion-exchange
chromatography. The purpose of eliminating dietary iod-
ide was to avoid any potential production of hypoiodite
(OI−) which is a hypohalide generated by the ovine oxida-
tive mucosal Duox/LPO/halide defense system in the
presence of sufficient iodide. Hypoiodite has been demon-
strated to be destructive to RSV [19]. All animal experi-
ments were approved by the Institutional Animal Care
and Use Committee (IACUC) of Iowa State University.
Post-mortem analysis of RSV disease severity
After euthanasia, the thorax was opened, lungs were re-
moved, gross lesions scored as described previously
[11,17,18] and photographed in situ and ex vivo. Tissue
samples were collected from all lung lobes of each ani-
mal in a standardized manner. Multiple samples from
each lobe were placed into cryovials and snap-frozen in
liquid nitrogen for subsequent use in RNA isolation for
hydrolysis probe-based reverse transcription real-time
quantitative polymerase chain reaction (RT-qPCR). Two
samples from each lobe were placed into tissue cassettes
and fixed in 10% neutral-buffered formalin (NBF) for
histological and immunohistochemical analysis, and two
lung samples from each animal were placed into
cryomolds and covered with CRYO-OCT Compound
(Tissue-Tek, Torrance, CA) then stored at −80°C until
cryosectioning. Immediately after lung removal, percent-
age parenchymal involvement was estimated for each
lobe. Group averages were calculated to obtain the gross
lesion score for each lobe [17,18].
In addition to the lung samples collected for RNA iso-
lation and histological samples, bronchoalveolar lavage
fluid (BALF) was collected from each lamb for determin-
ation of viral titers and cytology. BALF for viral titer as-
sessment was obtained by flushing the right caudal lung
lobe through a major bronchus with 5 mL of ice-cold
modified Iscove’s media (42.5% Iscove’s modified Dul-
becco’s medium, 7.5% glycerol, 1% heat-inactivated FBS,
49% DMEM, and 5 μg/mL kanamycin sulfate). 1 mL of
each recovered BALF sample was then used immediately
(never being frozen) for infectious focus assay. BALF for
cytology (~0.5 mL from each lamb) was obtained by
flushing a major bronchus of the accessory lobe with
1 mL PBS, pH 7.4. These BALF samples were submitted
to the clinical pathology laboratory (Iowa State Univer-
sity, College of Veterinary Medicine) for total nucleated
cell counts and slide preparation for cytology. An
ADVIA120™ automated hematology analyzer was used
to perform cell counts. Cytospin preparations of BALF
were performed using a Shandon Cytospin 3 set at
800 rpm (samples were spun for 10 minutes with low ac-
celeration). Slides were stained with modified Wright’s
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using a Hematek automated staining system. Differential
cell counts (based on a 300 cell differential) were per-
formed by a board-certified veterinary clinical patholo-
gist blind to the identity of the samples.
Histologic scores were determined by evaluating per-
cent consolidation and converting the observed percent-
age ranges to a simple integer based on a consolidation
scale used by our laboratory previously (35, 36): 0% con-
solidation = 0, 1-9% consolidation = 1, 10-39% consolida-
tion = 2, 40-69% consolidation = 3, 70-100% consolidation =
4 [17,18]. Group averages were calculated to obtain the
alveolar consolidation score.
RNA isolation and RT-qPCR
Tissues from right and left cranial, right and left middle,
and right and left caudal lung lobes (0.3-0.4 g of each)
were homogenized in TRIzol (Invitrogen), pooled in
equal (w/v) portions to create representative slurries for
each animal, each of which was adjusted to 0.091 g/mL
with additional TRIzol. Total RNA isolation continued
as per manufacturer’s guidelines (Invitrogen) followed by
DNase treatment (Ambion, TURBO DNase, Austin, TX)
and diluting the isolates 1:10 with a combination of
RNaseOUT (Invitrogen) and nuclease-free water (Ambion/
Invitrogen). A NanoDrop (Thermo Fisher Scientific) was
used to assess each sample for general RNA purity and
quantity (A260nm/A280nm all >1.98). In addition, Agilent
Bioanalyzer 2100 analysis of the RNA routinely showed
RIN values >8.0. RT-qPCR was carried out using One-
Step Fast qRT-PCR Kit mastermix (Quanta, BioScience,
Gaithersburg, MD) in a GeneAmp 5700 Sequence Detec-
tion System (Applied Biosystems, Carlsbad, CA) employ-
ing PREXCEL-Q for all set-up calculations [20-23].
Primers and probe for the RSV M37 nucleoprotein mRNA
sequence targeted by the RT-qPCR in this study were de-
signed using ABI Primer Express 2.0 based on RSV acces-
sion number M74568. Forward primer: 5’-GCTCTTAG
CAAAGTCAAGTTGAACGA; reverse primer: 5’-TGCTC
CGTTGGATGGTGTATT; hydrolysis probe: 5’-6FAM-
ACACTCAACAAAGATCAACTTCTGTCATCCAGC-TA
MRA. Prior to RT-qPCR, each 1:10-diluted total RNA
sample was further diluted so that each final reaction con-
tained 0.784 ng total RNA/μL; a dilution and sample con-
centration determined to be optimal by PREXCEL-Q
[19,20]. The GeneAmp 5700 Sequence Detection System
thermocycling conditions were 5 minutes at 50°C; 30 sec-
onds at 95°C; and 45 cycles of: 3 seconds at 95°C and
30 seconds at 60°C. Samples and standards were assessed
in duplicate wells and each quantification cycle (Cq)
was converted to a relative quantity (X0r) based on a
relative dilution standard curve using the equation: Xor =
EAMP
(b ‐Cq), where EAMP and b are the exponential PCR
amplification efficiency and the y-intercept values, re-
spectively, obtained from a sample mixture-derived
standard curve for RSV M37 nucleoprotein. The efficiency-
corrected delta Cq (EAMP
ΔCq) method was employed for
final quantification calculations. Results were normalized
to total tissue RNA loaded per reaction; identical for all
reactions as per the PREXCEL-Q protocol. No-RT control
reactions all proved negative for RSV and the assays were
determined to be free of inhibition based on the
PREXCEL-Q method [20-23].
Immunohistochemistry for RSV
Immunohistochemistry for localization, and relative quan-
tification of RSV antigen was performed on formalin-fixed
paraffin-embedded (FFPE) tissues [11,17,18]. After heating
for 15 minutes at 58°C and standard deparaffinization
through xylene and graded alcohols, antigen retrieval was
performed using TE-0.05% Tween 20, pH 9.0 and a
Decloaking Chamber™ Plus (Biocare Medical, Concord,
CA). A temperature of 125°C was reached in about 18 mi-
nutes, after which the system cooled to 80°C after another
22 minutes. Blocking for 15 minutes with 3% bovine
serum albumin (BSA) (Fisher Scientific, Hanover, IL) in
TBS-0.05% Tween 20, pH 7.4 (TBStw) and blocking with
20% normal swine serum (NSS) (Gibco/Invitrogen) in
TBStw for 15 minutes was followed by addition of a pri-
mary polyclonal goat anti-RSV (all antigens) antibody
(EMD/Millipore/Chemicon, Billerica, MA) which was ap-
plied for 1.5 hours at room temperature (~22°C) at a dilu-
tion of 1:500 (8–10 μg/mL) in TBStw containing 10% NSS
and 3% BSA. After TBStw rinses, biotinylated rabbit
anti-goat secondary antibody (Kirkegaard-Perry Labs,
Gaithersburg, MD) diluted 1:300 in TBStw containing
10% NSS and 3% BSA was applied for 45 minutes. Slides
were rinsed, blocked for endogenous peroxidase activity
(using 3% peroxide in TBStw) for 25 minutes, and
streptavidin-conjugated HRP (Invitrogen) diluted 1:200 in
TBStw was applied for 30 minutes. After rinsing slides
with TBStw, Nova Red (Vector, Burlingame, CA) was ap-
plied for about 90 seconds followed by water rinses, coun-
terstaining in Harris’ hematoxylin for 2 minutes, bluing
with alkaline Scott’s water for 1 minute, standard dehydra-
tion through graded alcohols and xylene, and cover-
slipping using Permount (Sigma, St. Louis, MO). Slides
(containing two pieces of lung tissue each) were scored
using the following procedure: 20 unique 10X fields on
each slide were assessed for antigen staining and immuno-
reactive cells were counted within bronchioles and alveoli.
The number of cells immunoreactive for RSV per field
was then scored as percent lobular involvement based on
the method used in our previous studies [17,18] without
using the non-parametric 1–4 scale assignment.
Statistical analysis
All analyses were performed using GraphPad Prism 6
(GraphPad Software Inc, La Jolla, CA). RT-qPCR, IHC
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and gross lesion data was assessed by one-way ANOVA
followed by Tukey’s post-test. All clinical data were
assessed by two-way ANOVA, and cumulative weight
change was additionally assessed by one-way ANOVA
followed by Tukey’s post-test. Scored parameters were
assessed using non-parametric (Kruskal-Wallis) and/or
unpaired, two-tailed, non-parametric Mann–Whitney
test analyses. Significance was accepted at P < 0.1 in
these evaluations.
Results
In-vitro studies
RSV in 0% sucrose concentration showed a 0.256 log
drop (44.52% loss) in infectivity due to freeze-thawing
and a 0.580 log drop (73.70% loss) due to nebulization;
indicating an overall log drop of 0.836 (85.41% loss in in-
fectivity) (Figure 1). RSV in 3% sucrose concentration
showed no log drop (0.00% loss) due to freeze-thawing
and a 0.831 log drop (85.25% loss) due to nebulization
representing an overall log drop of 0.694 (79.75% loss)
(Figure 1). RSV in 5% sucrose concentration showed a
0.198 log drop (36.61% loss) due to freeze-thawing and a
0.589 log drop (74.24% loss) due to nebulization yielding
an overall log drop of 0.787 (83.67% loss) (Figure 1).
RSV in 8% sucrose concentration showed no log drop
(0.00% loss) due to freeze-thawing and a 0.477 log drop
(66.67% loss) due to nebulization suggesting an overall
log drop of 0.448 (64.38% loss) (Figure 1). RSV in 10%
sucrose concentration showed no log drop (0.00% loss)
due to freeze-thawing and a 0.461 log drop (65.39% loss)
due to nebulization signifying an overall log drop of
0.362 (56.58% loss) (Figure 1). RSV in 15% sucrose con-
centration showed no log drop (0.00% loss) due to
freeze-thawing and a 0.398 log drop (60.00% loss) due to
nebulization indicating an overall log drop of 0.263
(45.46% loss) (Figure 1). RSV in 20% sucrose concentra-
tion showed no log drop (0.00% loss) due to freeze-
thawing and a 0.297 log drop (49.55% loss) due to nebu-
lization demonstrating an overall log drop of 0.266
(45.75% loss) (Figure 1).
In-vivo studies
Clinically, there were no significant differences in expira-
tory effort, weight gain, temperature, heart or respiratory
rates. There was a nearly-significant trend of increased
gross lesion scores (11 ± 5.9) for lambs receiving RSV in
20% sucrose compared to lambs lacking sucrose (5.7 ±
0.95) (Figure 2) and consolidation scores of histopatho-
logic lesions were significantly (P < 0.1) higher in lambs
receiving RSV in 20% sucrose (1.6 ± 0.2 estimated num-
ber) compared to lambs receiving RSV lacking sucrose
(1.2 ± 0.14 estimated number) (Figure 3). Also, histologi-
cally, neutrophil infiltration into infected bronchioles
was significantly increased (P < 0.1) in lambs receiving
RSV in 20% sucrose (0.9 ± 0.14 estimated number) com-
pared to lambs receiving RSV without sucrose (0.6 ± 0.1
estimated number) (Figure 4). To evaluate the effect of
RSV in 20% sucrose on inflammatory cell populations
within the lung, differential cell counts were performed
on BALF and significant differences in monocytes, lym-
phocytes, and neutrophils were not observed.
RSV viral titers from BALF fluid and RSV mRNA
levels in lung trended higher in lambs receiving RSV in
20% sucrose compared to lambs receiving RSV lacking
sucrose; controls lacked RSV viral titer and viral mRNA
(Figure 2). RSV viral antigen detected by immunohisto-
chemistry was significantly increased (P < 0.05) for anti-
gen levels in bronchioles of lambs receiving RSV in 20%
% Sucrose
FF
U 
/ m
l
0% 3% 5% 8% 10% 15% 20%
0
1.0 106
2.0 106
3.0 106
4.0 106
5.0 106 Stock titer
Freeze-thaw titer
Freeze-thaw-nebulization titer
Figure 1 Titer trends of M37 stock and M37 + sucrose solutions after freeze-thawing and freeze-thawing followed by nebulization. All
values have been factor-adjusted to a stock titer of 3 × 106.
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sucrose (17 ± 2.1) compared to antigen in bronchioles of
lambs receiving RSV without sucrose (5 ± 0.9) (Figure 5).
Also, RSV viral antigen scoring was significantly increased
in alveolar epithelium (P < 0.001) in lungs of lambs receiv-
ing RSV in 20% sucrose (35 ± 7.3) compared to lambs re-
ceiving RSV without sucrose (8.4 ± 1.9) (Figure 5).
Discussion
The use of sucrose to preserve and enhance infectivity/
virulence and to transport respiratory syncytial virus
(RSV) has been assessed previously but not, to our
knowledge, with nebulization. We suspected that there
could be a balance/give-and-take between the extent to
which sucrose stabilization may protect RSV from
damage by freeze-thaw, affect the virulence of the virus
in vivo and in vitro and mitigate potential effects of the
nebulization process itself. In 1968 it was shown that
44.5% sucrose was optimal for RSV storage at −70°C and
that this concentration of sucrose in cotton swabs
retained RSV viability for up to 7 days [12]. Another
study has shown that 0.2 M sucrose phosphate resulted
in significantly higher recovery of RSV as well as other
viruses (cytomegalovirus, varicella-zoster virus, herpes
simplex virus type 1) compared to 70% sorbitol [13].
Neither of these studies assessed nebulization nor did
they assess animal infection with recovered virus.
In this study, the addition of sucrose to RSV M37 af-
fected survival of virus during freeze-thawing, freeze-
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Figure 2 Gross lesion score, BAL titer of RSV and RNA levels of RSV detected in lung of lambs inoculated with RSV with and without
sucrose.
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Figure 3 Consolidation scores (histopathologic lesions) of lungs of lambs inoculated with RSV with and without sucrose by nebulization.
Lesions are significantly increased in lung of lambs inoculated with RSV containing sucrose compared to lambs receiving RSV lacking sucrose. Control
lambs lacked lesions. Control n = 2; M37 n = 6; M37 + sucr n = 6. Error bars represent SEM, *P < 0.1.
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thawing followed by nebulization, and the extent of viru-
lence in vivo. With freeze-thaw titers, there is an in-
crease in RSV titer (virus survival) with the addition of
sucrose concentrations compared to 0% (no) sucrose.
The variability in stock and freeze-thawing titers resulted
in some concentrations with freeze-thawing titers higher
than stock; however, these were not statistically signifi-
cant differences and we speculate that this might be
caused by the breaking up of viral aggregates during the
freeze-thaw process; thereby freeing up more infective
virions prior to titering by infectious focus assay. The
mechanism(s) by which sucrose may reduce viral loss
with freeze-thaw could not be determined and was not
further assessed in this study. For nebulization, a preser-
vation of titer (e.g., increased RSV viability) occurred
with higher sucrose concentrations compared to lower/
no sucrose concentrations. Furthermore, even though
RSV in 15 and 20% sucrose concentrations exhibited
limited viral titer loss, some loss did occur at these con-
centrations. Given the nearly-significant trends in the
titer data, sucrose seems to play a key role in RSV pro-
tection against the deleterious effects of both freeze-
thawing and freeze-thawing followed by nebulization.
The delivery of RSV in sucrose to lamb lung by nebuli-
zation also had an effect on virulence in vivo as reflected
by significantly increased consolidation scores (histo-
pathologic lesions), neutrophil infiltration into bronchi-
oles, and antigen levels (IHC scores). The reason(s) for
the increased virulence is likely due, at least in part, to
the increased survival of RSV throughout freeze-thawing
and the freeze-thawing-nebulization process on account
of the protective effect(s) of sucrose. Such increased
preservation of viable virions would effectively increase
the amount of infective virus deposited onto the respira-
tory mucosa. Although it is also possible that sucrose
enhances attachment or maintains virus survival within
the air-surface liquid (ASL) and/or positively affects
some other aspects of RSV virulence, exploring such
possibilities was not within the scope of this study. Su-
crose may also affect droplet size and aggregation of
viral particles which could alter the amount of virus per
droplet and affect infectivity. Reasonable considerations
for the positive effects on RSV stability include osmotic
activity of sucrose in preserving the viral envelope,
charge interactions between sucrose and the envelope,
and bridging by sucrose of other protective media com-
ponents to the viral envelope.
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Figure 4 Neutrophil infiltration scores into bronchioles of lungs
of lambs inoculated with RSV with and without sucrose by
nebulization. Neutrophils levels are significantly increased in lung
of lambs inoculated with RSV containing sucrose compared to lambs
receiving RSV lacking sucrose. Control lambs lacked neutrophil
infiltration. Control n = 2; M37 n = 6; M37 + sucr n = 6. Error bars
represent SEM, *P < 0.1.
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Figure 5 RSV antigen levels in lungs of lambs inoculated with RSV with and without sucrose by nebulization. RSV viral antigen levels are
significantly increased in both bronchioles (Br) and alveolar (Alv) epithelium of lung of lambs inoculated with RSV containing 20% sucrose compared
to lambs receiving RSV lacking sucrose. Control lambs lacked RSV antigen. Control n = 14; Br n = 42; Alv n = 42; Br + sucr n = 39; Alv + sucr n = 39. Error
bars represent SEM, *P < 0.05, ***P < 0.001.
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Although the addition of sucrose resulted in trends of
increased gross lesions, RSV mRNA levels and BAL ti-
ters in infected lambs, these differences were not signifi-
cant. This may be due to the timepoint post-infection
(six days) at which lesions are maximal; however, it is
possible that viral replication peaks at days 3–5 in lambs,
as it does in certain other models [11,12,17,18]. Thus, it
is possible that sucrose may have a significant effect on
gross lesions, RNA levels and viral titers but perhaps
earlier than the six-day timepoint post-nebulization. Be-
cause of the significance on some parameters and trends
of enhanced infectivity in others, sucrose addition ap-
pears to be beneficial in preserving virulence in such
studies.
Conclusions
This study provides important information on method-
ology of in vitro and in vivo studies with a human strain
of RSV and highlights the importance of carrying out
proof-of-concept studies. This is especially true for stud-
ies in lambs which are out-bred animals and which are
large enough to necessitate the use of larger volumes of
virus. Optimizing virus stability and ensuring consistency
in viral delivery are vital. While the nebulization method
is effective in the lamb and other experimental animal
models, these findings will also assist in comparison be-
tween studies in models that use different modes of
inoculation.
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